Presentation is loading. Please wait.

Presentation is loading. Please wait.

Response to Carfilzomib Therapy

Published byDewi Indradjaja Modified over 5 years ago

Similar presentations

Presentation on theme: "Response to Carfilzomib Therapy"— Presentation transcript:

1 Response to Carfilzomib Therapy
Response category %* All patients (n=257) Patients with baseline PN (n=202) Complete response (CR) 0.4 Very good partial response (VGPR) 5.1 Partial response (PR) 18.7 18.3 Minimal response (MR) 10.1 10 Stable disease (SD) 34.6 28.2 Progressive disease (PD) 26.8 33.1 Not Evaluable by IRC 4.4 5 Overall response rate (ORR) 24.1 23.7 Clinical benefit response (CBR=ORR + MR) 34.2 33.7 *Responses as assessed by the Independent Response Committee (IRC) PN= peripheral neuropathy 985

Download ppt "Response to Carfilzomib Therapy"

Similar presentations

Change in longest diameter = -19%. Change in sum of perpendicular diameters = -21%

Change in longest diameter = -19%. Change in sum of perpendicular diameters = -21%
Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.
Patient Outcomes Each patient will be evaluated at up to 4 time points (after 2, 4, 8 and 12 cycles) of therapy. Compared to the patient’s baseline evaluation,

Patient Outcomes Each patient will be evaluated at up to 4 time points (after 2, 4, 8 and 12 cycles) of therapy. Compared to the patient’s baseline evaluation,
Optimal Use of Newly Approved Agents – Carfilzomib and Pomalidomide Lymphoma-Myeloma Symposium October 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville,

Optimal Use of Newly Approved Agents – Carfilzomib and Pomalidomide Lymphoma-Myeloma Symposium October 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville,
Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.

Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.
Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.

Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.
1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.
Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.
Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach for Proteasome-Inhibitor Based Therapy in Waldenstrom’s.

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach for Proteasome-Inhibitor Based Therapy in Waldenstrom’s.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates.

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates.
Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.

Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.
Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.
RECIST Overview.

RECIST Overview.
Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract 5021. (Oral Presentation)

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)
A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide plus Low Dose Dex (Rd) (Phase III Spanish Trial): Persistent Benefit.

Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide plus Low Dose Dex (Rd) (Phase III Spanish Trial): Persistent Benefit.
Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.

Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

Similar presentations

Ads by Google